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Summary
 
Systemic autoimmune diseases are a genetically complex, heterogeneous group of disorders in
which the immune system targets a diverse but highly specific group of intracellular autoanti-
gens. The molecules targeted are not unified by common structure, function, or distribution in
control cells but become clustered and concentrated in surface blebs when cells undergo apop-
tosis. We show here that the majority of autoantigens targeted across the spectrum of human
systemic autoimmune diseases are efficiently cleaved by granzyme B in vitro and during cyto-
toxic lymphocyte granule–induced death, generating unique fragments not observed during
any other form of apoptosis. These molecules are not cleaved by caspase-8, although this pro-
tease has a very similar specificity to granzyme B. The granzyme B cleavage sites in autoanti-
gens contain amino acids in the P
 
2
 
 and P
 
3
 
 positions that are preferred by granzyme B but are
not tolerated by caspase-8. In contrast to autoantigens, nonautoantigens are either not cleaved
by granzyme B or are cleaved to generate fragments identical to those formed in other forms of
apoptosis. The striking ability of granzyme B to generate unique fragments is therefore an ex-
clusive property of autoantigens and unifies the majority of molecules targeted in this spectrum
of diseases. These results focus attention on the role of the cytotoxic lymphocyte granule–induced
death pathway in the initiation and propagation of systemic autoimmunity.
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T
 
he highly specific autoantibody response in systemic
autoimmune diseases generally predicts the biologic
phenotype of the disease, making autoantibodies diagnosti-
cally useful (1, 2). Although molecules targeted by the im-
mune system in these diseases are exceptionally diverse in
terms of structure, function, and subcellular distribution in
healthy cells, they are strikingly redistributed in apoptotic
cells, becoming clustered and concentrated in two popula-
tions of surface structures on the dying cell (3). It has been
proposed that cleavage of proteins might play a role in se-
lecting molecules as autoantigens, perhaps by cleavage-
induced revelation of cryptic epitopes (4, 5). In this regard,
several of the clustered antigens are substrates for caspases
during apoptosis. These include poly (ADP-ribose) poly-
merase (PARP),
 
1
 
 U1-70kD, the catalytic subunit of DNA-
dependent protein kinase (DNA-PK
 
cs
 
), the nuclear mitotic
apparatus protein (NuMA), nucleolus organizer region
(NOR)-90, fodrin, topoisomerase I, signal recognition par-
ticle (SRP)-72, and lamin B (6–10). However, the autoan-
tigen fragments produced by caspases during all forms of
apoptotic death described to date (including thymocyte ap-
optosis) are all identical, making it likely that caspase-
derived fragments have previously been generated during
apoptosis and tolerized centrally and peripherally (11, 12).
Furthermore, there are several autoantigens (fibrillarin,
centromere protein (CENP)-B, Ku, Ro, and La) that are
not cleaved by caspases during apoptosis, indicating that
susceptibility to cleavage by caspases is not a general feature
of autoantigens (for review see reference 13).
Granzyme B is a serine protease found in the cytoplasmic
granules of CTLs and NK cells that plays an important role
in inducing apoptotic changes in target cells during granule
exocytosis–induced cytotoxicity (14–16). This function is
achieved partly by catalyzing the cleavage and activation of
several caspases, as well as through caspase-independent
pathways (17–20). We recently demonstrated that gran-
 
1
 
Abbreviations used in this paper:
 
 CENP, centromere protein; CrmA, cy-
tokine response modifier 1; DTT, dithiothreitol; GC, granule contents;
FMK, fluoromethylketone; IAA, iodoacetamide; NuMA, nuclear mitotic
apparatus protein; NOR, nucleolus organizer region; PARP, poly (ADP-
ribose) polymerase; SRP, signal recognition particle. 
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zyme B (which shares with caspases a requirement for as-
partic acid in the substrate P
 
1
 
 position) efficiently cleaves
three caspase-3 substrates (DNA-PK
 
cs
 
, NuMA, and PARP),
generating novel fragments not generated during any other
form of cell death (21). To determine whether the genera-
tion of unique autoantigen fragments by granzyme B was a
universal feature of autoantigens, we assessed whether a
wide range of autoantigens was susceptible to cleavage by
granzyme B in vitro and in vivo. These studies demonstrate
that despite their diverse structure, distribution, and func-
tion, the majority of autoantigens in systemic autoimmune
diseases are efficiently cleaved by granzyme B, generating
unique fragments. In contrast, granzyme B either does not
cleave or does not generate unique fragments in all of the
nonautoantigen molecules that we tested. Granzyme B
cleavage sites in autoantigens were defined; in all cases, the
tetrapeptide sequence immediately adjacent to the cleavage
site was highly conserved. Cleavage by granzyme B there-
fore (a) unites these otherwise unrelated molecules and (b)
generates unique fragments of these antigens, strongly sug-
gesting that this protease plays a mechanistic role in select-
ing the molecules against which autoimmune responses are
initiated. These results highlight a potential role for the
CTL granule–induced death pathway in initiation and
propagation of autoimmunity.
 
Materials and Methods
 
Isolation of YT cell granule contents (GC) and purification of
granzyme B was as described (21). Purified caspase-3 and -8 and
CrmA (cytokine response modifier 1) were gifts from Nancy
Thornberry (Merck Research Labs., Rahway, NJ). cDNAs for
CENP-B, fibrillarin, topoisomerase I, and post meiotic segrega-
tion (PMS)1/PMS2 were gifts from Drs. Ann Pluta (University
of Maryland, Baltimore, MD), John Aris (University of Florida,
Gainesville, FL), Barbara White (University of Maryland, Balti-
more, MD), and Bert Vogelstein (Johns Hopkins University), re-
spectively. Autoantibodies to PMS1 and PMS2 are found in
3–5% of patients with autoimmune myositis (22). The patient se-
rum recognizing ribosomal protein
 
 
 
P was a gift from Dr. Keith
Elkon (The Hospital for Special Surgery, NY, NY). All data
shown represent 2–20 separate experiments.
 
HeLa Cell Culture and Induction of Apoptosis by UVB Irradia-
tion.
 
HeLa cells were passaged in 10% heat-inactivated calf se-
rum using standard tissue culture procedures. To induce apopto-
sis, cells were incubated with 1,650 J/m
 
2
 
 UVB and incubated
overnight (3). In Fig. 1 A, the gel samples used in the lanes
marked “Apoptotic Cells” consisted of pooled adherent and
floating populations.
 
In Vitro Cleavage of Endogenous Autoantigens in HeLa Lysates by
Caspase-3 or Granzyme B.
 
HeLa lysate was prepared as de-
scribed (6) and incubated at 37
 
8
 
C for 1 h with either 0.8 nM pu-
rified caspase-3 and 5 mM dithiothreitol (DTT) or purified
granzyme B (the concentrations used are specified in the legends
of Figs. 1 and 4) and 2 mM iodoacetamide (IAA). In the experi-
ment shown in Fig. 7 B, GC were added to lysates to induce
cleavage of autoantigens; the amount of GC used was based on its
granzyme B activity (1 
 
m
 
l of GC preparation contained the same
activity as 1 
 
m
 
l of purified granzyme B). To inhibit granzyme B
activity in HeLa lysates, equimolar amounts of CrmA and
 
granzyme B (in GC) were preincubated at 37
 
8
 
C for 5 min before
adding to HeLa lysates. All samples were electrophoresed on 10%
SDS-PAGE, with the exception of Ki-67 (7.5% SDS-PAGE).
Proteins were then transferred to nitrocellulose or polyvinylidene
difluoride and immunoblotted with patient sera recognizing Mi-2,
PARP, SRP-72, U1-70kD, topoisomerase I, Ro-52, Ro-60, ri-
bosomal protein P, Ku-80, or mAb to Ki-67 (Sigma Chemical
Co.). Proteins were detected using horseradish peroxidase–labeled
secondary antibodies and chemiluminescence (Pierce Chemi-
cal Co.).
 
In Vitro Cleavage of Endogenous Autoantigens in IAA-treated HeLa
Cell Lysates by Caspase-8.
 
HeLa lysate was prepared as described
(23), except that DTT was omitted from the lysis buffer. To inac-
tivate endogenous caspase activities, 1 mM IAA was added to the
lysates (see Fig. 9, all lanes except 3 and 6) and incubated for 15
min at 4
 
8
 
C. 5 mM DTT was then added in the absence or pres-
ence of 50 nM caspase-8, and the reactions were incubated for
1 h at 37
 
8
 
C. Before using the “IAA poisoning protocol” in the
caspase-8 experiments, the validity of this experimental approach
to inactivate endogenous caspases present in lysates while still
permitting exogenously added caspases to cleave was tested. As
PARP and U1-70kD are well characterized caspase-3 substrates
(generating signature fragments of 89 and 40 kD, respectively [23]),
their ability to be cleaved by caspase-3 in IAA-treated lysates was
used in the following defined test system: (i) HeLa lysates con-
taining 0.8 nM caspase-3 and 5 mM DTT were incubated for 1 h
at 37
 
8
 
C; the extent of PARP (66%) and U1-70kD (25%) cleavage
obtained under these conditions represented maximum possible
caspase-3 activity. (ii) 1 mM IAA was added to HeLa lysates pre-
pared in the absence of DTT. After incubating for 15 min at 4
 
8
 
C,
0.8 nM caspase-3 was added and the lysates were further incu-
bated (1 h at 37
 
8
 
C); PARP and U1-70kD were not cleaved un-
der these conditions. (iii) HeLa lysates were incubated as in (ii),
except that 5 mM DTT was added simultaneously with caspase-3
after the IAA poisoning step. Both PARP and U1-70kD were
cleaved (the amounts of cleavage were 80 and 70%, respectively,
of that noted in approach [i]), confirming that exogenous caspases
are active in these lysates in which endogenous caspases have pre-
viously been inactivated if subsequently added with DTT. Aboli-
tion of the contribution of endogenous caspases under these cir-
cumstances accounts for the decreased total substrate cleavage
observed.
 
In Vitro Cleavage of [
 
35
 
S]methionine-labeled Autoantigen Substrates
Generated by In Vitro Transcription/Translation.
 
[
 
35
 
S]methionine-
labeled CENP-B, fibrillarin, PMS1, and PMS2 were generated
by coupled in vitro transcription/translation (23). Cleavage reac-
tions were performed in buffer A consisting of 10 mM Hepes, pH
7.4, 2 mM EDTA, and 1% NP-40 (5 mM DTT was added to the
reactions containing caspases). Reactions contained the amounts
of caspase-3 and granzyme B indicated in the figure legends and
were incubated at 37
 
8
 
C for either 15 or 60 min, as specified. Af-
ter terminating the reactions by adding gel buffer and boiling,
samples were electrophoresed on 10% SDS-PAGE (CENP-B,
PMS1, and PMS2) or 12% SDS-PAGE (fibrillarin), and their
fragments were visualized by fluorography.
 
In Vitro Cleavage of [
 
35
 
S]methionine/cysteine-labeled Endogenous
Autoantigen Substrates after Immunoprecipitation with Patient Sera.
 
HeLa cells were labeled for 2 h with [
 
35
 
S]methionine/cysteine,
and the lysates were immunoprecipitated with patient sera recog-
nizing histidyl tRNA synthetase, RNA polymerase II large sub-
unit, PMScl, or alanyl tRNA synthetase, followed by protein
A–agarose. The beads, containing washed, radiolabeled endoge-
nous proteins were resuspended in buffer A in the presence or 
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absence of granzyme B and incubated for 15 min at 37
 
8
 
C. The
following amounts of granzyme B were used: 46 nM histidyl
and alanyl tRNA synthetases and 23 nM RNA polymerase II and
PMScl. Samples were electrophoresed on 10% SDS-PAGE, and
radiolabeled proteins and their fragments were visualized by fluo-
rography.
 
In Vitro Cleavage of Endogenous and Purified Nonautoantigen Sub-
strates.
 
HeLa lysates were incubated with granzyme B for 1 h
at 37
 
8
 
C and then electrophoresed on 8 or 10% SDS-PAGE and
immunoblotted with a rabbit polyclonal antibody to Cdc2p34
(Santa Cruz Biotechnology) or mAbs to vinculin or 
 
b
 
-tubulin
(Sigma Chemical Co.). Cleavage of purified human lactoferrin,
apotransferrin, and thrombin (all from Sigma Chemical Co.) was
performed by incubating 20 
 
m
 
g of each substrate in the absence
or presence of 30 nM granzyme B for 60 min at 37
 
8
 
C. The reac-
tions were terminated by adding gel application buffer, and the
samples were electrophoresed on 10% SDS-PAGE and visualized
by Coomassie blue staining. Similar amounts of purified La were
well cleaved under identical conditions (data not shown).
 
Calculation of Catalytic Constant (k
 
cat
 
/K
 
m
 
) Values. k
 
cat
 
/
 
K
 
m
 
 values
were determined as described (21, 23) using endogenous sub-
strates in cell lysates, radiolabeled endogenous immunoprecipi-
tated substrates, or radiolabeled substrates generated by coupled
in vitro transcription/translation. The percent cleavage of each
substrate was determined by densitometry; these values were fit-
ted to the first order rate equation,
 
 
 
to calculate 
 
k
 
cat
 
/
 
K
 
m
 
. For several of the autoantigens listed in Ta-
ble I, 
 
k
 
cat
 
/
 
K
 
m
 
 values were obtained using two or all three of these
methods, and equivalent results were obtained (reference 21; data
not shown).
 
Cleavage of Endogenous Substrates after In Vivo Incubation of Fas-
negative K562 Cells with YT Cell GC or Lymphokine-activated Killer
Cells.
 
K562 cells were incubated with YT cell GC as described
(21), except that the incubations were done in HBSS containing
10 mM Hepes, pH 7.4. Cells were incubated for 2 h at 37
 
8
 
C in
the absence or presence of added GC, before terminating reac-
tions by adding 2
 
3
 
 SDS–gel buffer directly to cell suspensions.
Similar experiments were performed using cultured HeLa cells,
human umbilical vein endothelial cells, human myoblasts, and
Jurkat cells with identical results (data not shown). LAK cells
were prepared and incubated with K562 target cells at a 3:1 ratio
in the absence or presence of 100 
 
m
 
M Ac-DEVD-CHO or 50
 
m
 
M Z-IETD-fluoromethylketone (FMK; Calbiochem Corp.) as
described (21). Incubation of either LAK or K562 cells individu-
ally with these inhibitors did not affect the autoantigens analyzed
(data not shown).
 
Confirmation of Granzyme B Cleavage Sites by Mutagenesis of P
 
1
 
Aspartic Acid Residues.
 
cDNA clones encoding fibrillarin, La,
U1-70kD, Mi-2, PMS1, PMS2, and topoisomerase I were used
as templates for mutagenesis by overlap-extension PCR to gener-
ate clones containing putative granzyme B site P
 
1
 
 Asp
 
®
 
Ala sub-
stitutions (21). [
 
35
 
S]methionine-labeled polypeptides were gener-
ated by coupled in vitro transcription/translation and used as
substrates for granzyme B cleavage as described above.
 
Results
 
Granzyme B Specifically and Efficiently Cleaves Numerous
Autoantigens Targeted in Systemic Autoimmune Diseases.
 
We
initially determined whether and how efficiently a variety
% substrate cleavage 100 1 ( e
kcat E [] × Km  time × ¤ –
) – ´ , =
 
of well-defined autoantigens across the spectrum of systemic
autoimmune diseases were cleaved by purified granzyme B
(Table I). We used autoantibodies of known specificity to
immunoblot lysates of HeLa cells that had been incubated
in vitro with or without granzyme B. Lysates were pre-
treated with IAA (which covalently modifies the active site
cysteine of caspases) to prevent endogenous caspase activ-
ity. Interestingly, several autoantigens that have previously
been shown to be cleaved by caspases during apoptosis
were also efficiently cleaved by granzyme B, generating
unique fragments in every case. These substrates included
U1-70kD, topoisomerase I, SRP-72, PARP (Fig. 1), and
NOR-90 (data not shown). We also identified Mi-2, Ki-
67, PMS1, PMS2, and La as additional autoantigens that
are cleaved by both caspases and granzyme B; again, distinct
 
Table I.
 
Autoantigens Are Efficiently Cleaved by Granzyme B
 
No. Autoantigen Cleavage site
 
k
 
cat
 
/
 
K
 
m
 
M
 
2
 
1
 
.s
 
2
 
1
 
1 DNA-PK
 
cs
 
VGPD
 
2,698
 
-F 2.5 
 
6
 
 0.8 
 
3
 
 10
 
6
 
2 Topoisomerase I IEAD
 
15
 
-F 1.6 
 
6
 
 0.6 
 
3
 
 10
 
6
 
3 NuMA VATD
 
1,705
 
-A 5.4 
 
6
 
 1.4 
 
3
 
 10
 
5
 
4 Mi-2 VDPD
 
1,312
 
-Y 8.5 
 
6
 
 1.9 
 
3
 
 10
 
4
 
5 La LEED
 
220
 
-A 6.1 
 
6
 
 1.7 
 
3
 
 10
 
4
 
6 PMS1 ISAD
 
496
 
-E 6.9 
 
6
 
 0.9 
 
3
 
 10
 
4
 
7 Fibrillarin VGPD
 
184
 
-G 3.3 
 
6
 
 1.9 
 
3
 
 10
 
4
 
8 PARP VDPD
 
536
 
-S 2.3 
 
6
 
 1.8 
 
3
 
 10
 
4
 
9 U1-70kD LGND
 
409
 
-S 1.3 
 
6
 
 0.4 3 104
10 PMS2 VEKD493-S 1.4 6 0.6 3 104
11 Isoleucyl tRNA VTPD983-Q 7.8 6 1.8 3 104
synthetase
12 Histidyl tRNA LGPD48-E 2.3 6 0.7 3 104
synthetase
13 Alanyl tRNA VAPD632-R 1.8 3 104
synthetase
14 RNA polymerase I ICPD448-M 1.3 6 0.5 3 104
15 Ki-67 VCTD1481-K 8.1 6 2.6 3 103
16 PMScl VEQD252-M 7.5 6 1.4 3 103
17 CENP-B VDSD457-E 5.9 6 0.2 3 103
18 RNA polymerase II ITPD370-P ND
19 SRP-72 VTPD573-P ND
20 Ku-70 ISSD79-R ND
21 NOR-90 VRPD220-A ND
Catalytic constant (kcat/Km) values were determined as described in Ma-
terials and Methods using defined amounts of purified granzyme B to
cleave either radiolabeled substrates expressed by in vitro transcription/
translation, endogenous substrates in cell lysates, or radiolabeled endoge-
nous immunoprecipitated substrates. Likely granzyme B cleavage sites
were predicted using fragment sizes and the known cleavage specificity
of granzyme B (29, 30). For autoantigens 1–10, the predicted cleavage
sites were confirmed by showing that molecules having P1Asp®Ala
substitutions were no longer cleaved by granzyme B (see Fig. 8).818 Susceptibility to Granzyme B Cleavage Predicts Autoantigen Status
fragments were generated by the two proteases (Figs. 1, 2,
and 8). Whenever possible, efficient cleavage by granzyme
B and generation of novel fragments was confirmed using
both endogenous substrates in lysates (detection by immu-
noblotting) and in vitro–translated substrates (detection by
fluorography; this was done for U1-70kD, PARP, NuMA,
topoisomerase I, La, PMS1, and Mi-2). The kcat/Km values
varied between 1.3 3 104 M21.s21 (U1-70kD) and 1.6 3
106 M21.s21 (topoisomerase I) (Table I). Several substrates
were cleaved by granzyme B at multiple sites (e.g., Mi-2,
Ki-67, PMS1, and PMS2; Figs. 1 and 2), generating a com-
plex profile of cleavage fragments.
Previous studies have identified several autoantigens that
are not susceptible to cleavage by caspases during apoptosis
(7, 9). Using the immunoblotting system described above
and/or cleavage assays using in vitro–translated substrates,
we demonstrated that many of these autoantigens are effi-
ciently cleaved by granzyme B. These molecules included
fibrillarin, Ku-70, and RNA polymerase II large subunit.
(Figs. 2 and 3; see Fig. 5). As some well-defined autoanti-
bodies do not recognize their antigens by immunoblotting,
we also addressed the susceptibility of radiolabeled endoge-
nous substrates to cleavage by granzyme B in vitro. To per-
form these studies, HeLa cells were radiolabeled with
[35S]methionine/cysteine, and proteins were immunopre-
cipitated using human autoantibodies. Protein A–agarose
beads containing washed, precipitated proteins were resus-
pended in buffer supporting the activity of granzyme B and
incubated in the absence or presence of added purified
granzyme B. To confirm the validity of this approach, we
tested several different autoantigens known to be cleaved
by granzyme B, as well as several autoantigens and nonau-
toantigens that are not cleaved by granzyme B. The cleav-
age profiles obtained after incubating granzyme B with (a)
lysates (followed by detection with immunoblotting) or
(b) immunoprecipitated radiolabeled antigens (followed by
detection with fluorography) were compared. Identical re-
sults were obtained using these two methods for cleaved
autoantigens (topoisomerase I, Mi-2, RNA polymerase II
large subunit, Ku-70, PARP, La, and NOR-90), un-
cleaved autoantigens (Ku-80, Ro-60kD), and control sub-
strates (b-tubulin, vinculin). Using this immunoprecipita-
tion approach, we demonstrated that several additional
autoantigens (PMScl, RNA polymerase I and II large sub-
units, histidyl tRNA synthetase, isoleucyl tRNA syn-
thetase, and alanyl tRNA synthetase) were indeed cleaved
by granzyme B, generating unique fragments (Table I; Fig.
3 contains representative examples). Using identical im-
munoprecipitation conditions, these substrates were not
cleaved by caspase-3, whereas Mi-2 cleavage by caspase-3
occurred normally (data not shown). Several autoantigens
were not susceptible to cleavage by either caspases or
granzyme B (Fig. 4 and references 7, 9, 24). These included
Ro-52kD and -60kD, ribosomal protein P, histones, Sm
proteins, threonyl tRNA synthetase, glycyl tRNA syn-
thetase, and Ku-80.
Susceptibility to cleavage by granzyme B was a highly
specific feature of autoantigens; nonautoantigens were ei-
Figure 1. Endogenous autoantigens are cleaved by granzyme B, generating unique frag-
ments. (A) Gel samples were prepared from control and apoptotic (UVB-irradiated) HeLa
cells and from HeLa lysate incubated in vitro with 0.8 nM purified caspase-3 and 5 mM
DTT or 42 nM granzyme B and 2 mM IAA. 75-mg aliquots were electrophoresed in each
gel lane, and autoantigens were detected by immunoblotting. Indicator lines denote intact
antigens (Mi-2, 240 kD; PARP, 113 kD; SRP-72, 72 kD; Ki-67, 395 kD; U1-70kD, 70
kD; and topoisomerase I, 100 kD). Solid arrowheads mark granzyme B–specific fragments
(Mi-2, 75, 72, and 48 kD; PARP, 110, 72, 62, and 55 kD; SRP-72, 62 kD; Ki-67, 167 and
148 kD; U1-70kD, 60 kD; topoisomerase I, 98, 75, and 72 kD). Open arrowheads denote
fragments generated during apoptosis (Mi-2, 50 and 58 kD; PARP, 89 kD; SRP-72, 68
kD; Ki-67, 155, 140, 130, and 110 kD; U1-70kD, 40 kD; topoisomerase I, 70 kD). Note
that the PARP autoradiogram shown was optimized for visualization of intact PARP and
the 89-kD fragment; the 72- and 62-kD granzyme B–specific PARP fragments are clearly
seen on longer autoradiogram exposures. (B) HeLa lysates were incubated for 1 h in the ab-
sence of protease (leftmost lane) or with the increasing amounts of granzyme B indicated.
The samples were blotted with topoisomerase I antibodies. The data shows that the cleavage
site that generates the 98-kD fragment from the 100-kD intact antigen (IEAD15-F; Table I)
is exquisitely sensitive to granzyme B, with z70% of topoisomerase I cleaved to the 98-kD
form after incubation with 0.42 nM granzyme B. Note that the 75- and 72-kD fragments
are only generated after incubation with 10-fold higher concentrations of granzyme B.819 Casciola-Rosen et al.
ther not cleaved by granzyme B (Fig. 4) or were cleaved
but without producing novel fragments (25–27). The fol-
lowing human molecules were not cleaved by granzyme B:
a1-antitrypsin,  b-tubulin, apotransferrin, C3 (b chain),
carbonic anhydrase, CDC2 p34, C-reactive protein, glu-
tathione S-transferase, glycogen phosphorylase, hemoglo-
bin, IgG, lactoferrin, lysozyme, orosomucoid, thrombin a
chain, thrombin b chain, and vinculin. Procaspases 3 and 7,
which have not been found to be autoantigens during
screening of .500 autoimmune sera by immunoblotting
(Casciola-Rosen, L., and A. Rosen, unpublished data), are
efficiently cleaved by both granzyme B and caspase-8, gen-
erating identical fragments (25–27).
Thus, in addition to the three autoantigens we have pre-
viously described as being cleaved by both caspase-3 and
granzyme B (DNA-PKcs, NuMA, PARP), these studies
identify an additional nine autoantigens that are cleaved by
both proteases but at different sites. Furthermore, another
nine autoantigens are cleaved exclusively by granzyme B
and not by caspases. Therefore, 21 autoantigens targeted
across the spectrum of human systemic autoimmune dis-
eases are efficiently cleaved by granzyme B, generating
unique fragments not observed during other forms of cell
death.
Granzyme B Cleavage Fragments Are Generated During
CTL Granule–mediated Target Cell Death. To confirm that
similar autoantigen fragments are generated in intact cells
during granule-induced cell death, we exposed K562 cells
to YT cell GC and analyzed the biochemical status of the
autoantigens by immunoblotting. In those cases where au-
toantigens are substrates for both caspases and granzyme B,
signature fragments of both proteases were generated (U1-
70kD, topoisomerase I, PARP [Fig. 5], La, Mi-2, and Ki-
67 [data not shown]). The amount of granzyme B–specific
fragments generated was enhanced in the presence of 100
mM Ac-DEVD-CHO, a caspase inhibitor (see below). Au-
toantigens known to be cleaved only by granzyme B were
also cleaved in the K562/YT granule system; the granzyme
B–specific fragments of Ku-70, RNA polymerase II large sub-
unit (Fig. 5), and PMS1 (data not shown) were generated. 
We next determined whether autoantigens cleaved by
granzyme B in vitro are cleaved during killing of Fas-nega-
tive target cells by LAK cells. Granzyme B–specific frag-
ments of Mi-2, topoisomerase I, U1-70kD, and SRP-72
(Fig. 6), as well as PMS1, Ku-70, and La (data not shown),
are generated during this form of cell death. For the anti-
gens shown in Fig. 6, which are directly cleaved by both
caspase-3 and granzyme B, the amounts of granzyme
B–specific fragments are determined by the relative effi-
ciency of cleavage by the two proteases (Table II). Thus,
granzyme B–mediated cleavage of topoisomerase I is z50-
Figure 2. [35S]methionine-labeled autoantigen substrates generated by
in vitro transcription/translation are cleaved by purified granzyme B.
[35S]methionine-labeled CENP-B, fibrillarin, PMS1, and PMS2 were in-
cubated for 60 min at 378C with the following amounts of caspase-3: 1 nM
(PMS2) or 2.5 nM (CENP-B, fibrillarin, and PMS1). Separate incuba-
tions were performed as follows with granzyme B: 62.5 nM, 15 min
(fibrillarin, PMS1); 42 nM, 60 min (CENP-B); and 28 nM, 60 min
(PMS2). The samples were electrophoresed and visualized as described in
Materials and Methods. Open arrowheads denote intact antigens (CENP-B,
80 kD; fibrillarin, 37 kD; PMS1, 110 kD; PMS2, 105 kD). Solid arrow-
heads mark the granzyme B–specific fragments (CENP-B, 58 and 40 kD;
fibrillarin, 17 kD; PMS1, 50 and 60 kD; PMS2, 60, 50, and 36 kD).
Figure 3. Immunoprecipitated endogenous autoantigens are cleaved by
purified granzyme B. [35S]methionine/cysteine-labeled endogenous histi-
dyl tRNA synthetase, RNA polymerase II, PMScl, and alanyl tRNA syn-
thetase were immunoprecipitated and cleaved by granzyme B as described
in Materials and Methods. Solid arrowheads denote granzyme B–specific
fragments (histidyl tRNA synthetase, 40 kD; RNA polymerase II large
subunit, 190, 110, and 92 kD; PMScl, 85 and 74 kD; alanyl tRNA syn-
thetase, 58 kD).
Figure 4. Numerous proteins are not cleaved by granzyme B. HeLa
cell lysates were incubated for 60 min in the absence or presence of 42 nM
granzyme B, followed by gel electrophoresis of 75-ml aliquots. The sus-
ceptibility of the autoantigens Ro (52 and 60 kD), ribosomal protein P,
Ku-80, and nonautoantigens vinculin, b-tubulin, and Cdcp34 to cleavage
by granzyme B was assessed by immunoblotting. Although none of these
molecules was cleaved, efficient cleavage of NuMA, PARP, and U1-
70kD in these lysates confirmed granzyme B activity (data not shown).
The ability of granzyme B to cleave the purified nonautoantigens lacto-
ferrin, apotransferrin, and thrombin was examined by incubating 20 mg of
each substrate in the absence or presence of 30 nM granzyme B for 60
min at 378C, followed by Coomassie blue staining of SDS-PAGE.820 Susceptibility to Granzyme B Cleavage Predicts Autoantigen Status
fold more efficient than cleavage by caspase-3, and
granzyme B–specific fragments are the most prominent
(Fig. 6, lane 3; note that in lanes 3 and 4, the majority of
topoisomerase is in the 98-kD granzyme B–cleaved form).
Where the efficiency of substrate cleavage by granzyme B
and caspase-3 are similar (e.g., DNA-PKcs and Mi-2), both
caspase- and granzyme B–specific fragments are generated.
Inhibition of caspases abolishes the caspase-specific frag-
ments only. In contrast, where substrates are cleaved
z200-fold more efficiently by caspase-3 than by granzyme
B (PARP, U1-70kD), no granzyme B–specific fragments
were observed in the intact cell killing assay unless caspases
were inhibited by adding Ac-DEVD-CHO (Fig. 6; com-
pare lanes 3 and 4).
Production of unique autoantigen fragments in the LAK
cell assay was decreased by inhibitors of granzyme B (28).
Thus, 50 mM of Z-IETD-FMK (Fig. 7 A) greatly dimin-
ished cleavage of NuMA, Mi-2, and topoisomerase I, as
evidenced by the increased amount of intact antigen de-
tected by blotting (Fig. 7 A; compare lanes 3 and 4). This
was accompanied by an abolition of the unique cleavage
fragments of NuMA (175 kD) and topoisomerase I (98, 75,
and 72 kD) and markedly inhibited the production of
granzyme B–specific fragments of Mi-2 (48 kD). This pat-
tern of inhibition correlated well with the efficiency of
cleavage of these substrates by granzyme B (Table II). As
noted above, production of granzyme B–specific fragments
of autoantigens was either unchanged (Mi-2) or enhanced
(PARP, U1-70kD, SRP-72) by treatment with the
caspase-specific inhibitor, Ac-DEVD-CHO (Fig. 6, lane
4). Similar results were also obtained when 143 nM CrmA
was used to inhibit granzyme B activity in cell lysates in
which granzyme B–specific fragments of U1-70kD and
PARP were abolished (Fig. 7 B), with concomitant recov-
ery of intact antigen. Although both Z-IETD-FMK and CrmA
also inhibit group III caspases, unique fragments of these
autoantigens are not generated by these proteases (see Fig. 9).
Granzyme B Cleaves Autoantigens at Highly Conserved
Sites. The specificity of granzyme B has recently been de-
fined using a positional scanning combinatorial tetrapeptide
library (29, 30). The protease has a preference for I, V, or L
in P4, E, G, or S in P3, and P, S, N, A, Q, H, T, V, E, or D
in P2, with a near absolute preference for D in P1. This spec-
ificity and the sizes of the fragments generated by granzyme
B cleavage were used to predict cleavage sites. Using site-
directed mutagenesis to make a series of P1 Asp®Ala substi-
tutions in several of the granzyme B substrates, we addressed
the effects of mutation on the efficiency of cleavage by the
protease and thus defined the granzyme B cleavage sites in
fibrillarin, Mi-2, topoisomerase I, PMS1, PMS2, La, and
U1-70kD (Table I; Fig. 8 contains representative examples).
The granzyme B cleavage sites in PARP and DNA-PKcs
were defined previously (21, 31). In every case, the cleavage
site sequence is in accord with the specificity determined by
the combinatorial library. The P2 and P3 residues in these
cleavage sites were quite restricted, with prominent repre-
sentation of P, A, and S in P2 and G, E, T, D, and S in P3.
Interestingly, many of these residues are preferred by
granzyme B but not by group III caspases (29). Using frag-
ment sizes to predict likely granzyme B cleavage sites in
other autoantigens, we readily identified probable cleavage
sites in these proteins (Table I). Other than the consensus
tetrapeptide sequence preceding the cleavage site in these au-
toantigens, there were no obvious similarities in primary se-
quence either upstream or downstream of this site. Interest-
ingly, several granzyme B substrates also have consensus
tetrapeptide sequences that are not cleaved, indicating that
additional conformational information influences susceptibil-
ity to cleavage at these sites.
Figure 5. Granzyme B–specific autoantigen fragments are generated af-
ter in vivo incubation of intact K562 cells with YT cell GC. K562 cells
were incubated in the absence (2) or presence (1) of YT cell GC for 2 h
at 378C. After terminating the reactions by adding gel buffer, 55 mg of
protein was electrophoresed in each gel lane, and the samples were im-
munoblotted with monospecific patient sera. Solid and open arrowheads
mark the positions of the granzyme B–specific and caspase-specific frag-
ments, respectively.
Figure 6. Granzyme B–specific
autoantigen fragments are generated
in K562 cells attacked by LAK cells.
LAK cells were incubated with
K562 cells in the absence or pres-
ence of 100 mM Ac-DEVD-CHO
(21). After terminating the reactions,
the following numbers of cells were
electrophoresed in each gel lane: 3 3
105 LAK cells (lane 1); 105 K562
cells (lane 2); 3 3 105 LAK cells plus
105 K562 cells (lanes 3 and 4). Au-
toantigens were detected by immu-
noblotting with monospecific patient
sera. Solid and open arrowheads mark
the positions of granzyme B–specific
and caspase-specific fragments, re-
spectively; indicator lines denote the
intact antigens.821 Casciola-Rosen et al.
Autoantigens That Are Cleaved by Granzyme B Are Not
Substrates for Caspase-8. In addition to the granule exocy-
tosis pathway, CTLs can also induce target cell proteolysis
and apoptosis through ligation of target cell Fas by CTL Fas
ligand (32). As caspase-8 is prominently activated when
CTLs induce target cell death through the Fas pathway (33)
and because group III caspases have a very similar substrate
specificity to granzyme B (29), we determined if caspase-8
could generate the same proteolytic fragments of endoge-
nous autoantigens in cell lysates that are generated by
granzyme B. As caspase-8 efficiently activates precursor ef-
fector caspases in cell lysates (which in turn efficiently
cleave downstream substrates), we first irreversibly inacti-
vated these caspase precursors with IAA. Exogenous
caspase-8 was then added in the presence of excess DTT,
and substrate cleavage was assayed by immunoblotting. We
initially confirmed that caspase-8 was active in the lysate
system by using a coupled proteolysis system to demon-
strate cleavage of downstream caspase-3 substrates (see Ma-
Table II. Relative Cleavage Efficiencies Determine Ratio of Substrate Fragments Generated In Vivo
Autoantigen
kcat/Km (M21.s21) for cleavage
Prominent fragment type
generated in:
Caspase-3 Granzyme B LAK/K562 system
Topoisomerase-I 3.4 3 104 1.6 3 106 Granzyme B
DNA-PKcs 7.5 3 106 2.5 3 106 Granzyme B/caspase-3
Mi-2 2.0 3 105 8.5 3 104 Granzyme B/caspase-3
U1-70kD 2.5 3 106 1.3 3 104 Caspase-3
PARP 5.0 3 106 2.3 3 104 Caspase-3
Autoantigens that are cleaved by granzyme B with similar or greater efficiency than by caspase-3 give rise to prominent granzyme B fragments in the
LAK/K562 system. In this system, granzyme B fragments are not observed when substrates are cleaved less efficiently by granzyme B than by
caspase-3, unless caspases are inhibited (see Fig. 6). kcat/Km values for caspase-3 cleavage of DNA-PKcs, PARP, and U1-70kD are from reference 23,
and values for granzyme B cleavage of DNA-PKcs and PARP are from reference 21. The remaining kcat/Km values were calculated as described in
Materials and Methods.
Figure 7. Generation of unique autoantigen fragments is abolished by
Z-IETD-FMK or CrmA. Indicator lines denote the positions of intact
antigens; solid and open arrowheads denote the granzyme B–specific and
caspase-specific fragments, respectively. (A) LAK and K562 cells were
preincubated in the absence or presence of 50 mM Z-IETD-FMK and
then coincubated (E/T ratio of 3:1) for an additional 4 h (21). The sam-
ples were electrophoresed and autoantigens were blotted as described in
the Fig. 6 legend. (B) GC were preincubated in the absence or presence
of an equimolar amount of CrmA (amounts based on the granzyme B
content of GC) for 5 min at 378C. HeLa lysates were then incubated with
these GC for a further 60 min at 378C (0.5 ml GC per 75 mg lysate) be-
fore electrophoresis and immunoblotting. 
Figure 8. Granzyme B cleavage of fibrillarin and La is abolished by P1
D®A mutation. Site-directed mutation of aspartic acid residues in the P1
positions of fibrillarin (D184®A) and La (D220®A) was performed. Wild-
type (WT) and mutated products were generated by in vitro transcrip-
tion/translation before cleavage with granzyme B as described in Materi-
als and Methods. Open and solid arrowheads mark the positions of intact
molecules and granzyme B–specific fragments, respectively. Similar results
were obtained when P1 aspartic acid residues in the granzyme B cleavage
sites of U1-70kD, Mi-2, PMS1, PMS2, and topoisomerase I were mu-
tated (data not shown).822 Susceptibility to Granzyme B Cleavage Predicts Autoantigen Status
terials and Methods; Fig. 9). None of the autoantigens
cleaved by granzyme B was cleaved by caspase-8; data for
Mi-2, topoisomerase I, Ku-70, and RNA polymerase II
large subunit are shown in Fig. 9.
Discussion
Autoantibodies Found in Human Autoimmune Diseases Rec-
ognize a Group of Substrates Efficiently Cleaved by Granzyme B
During CTL-mediated Apoptosis. We have demonstrated
that components of 21 out of 29 well-defined autoantigens
are susceptible to efficient cleavage by granzyme B, gener-
ating unique fragments. Although the cleaved molecules
differ markedly in subcellular location, function, and ex-
tended primary sequence, they share two features: (a) all are
autoantigens targeted by a high titer autoantibody response
in human autoimmune diseases, including systematic lupus
erythematosus, Sjogren’s syndrome, diffuse and limited
scleroderma, and autoimmune myositis; and (b) molecules
are unified by containing a granzyme B cleavage site not
susceptible to cleavage by caspase-8. The status of a mole-
cule as an autoantigen and its unique susceptibility to cleav-
age by granzyme B but not by caspase-8 are therefore
highly related (P , 0.0001, chi-square analysis). The posi-
tive predictive value of susceptibility to unique cleavage by
granzyme B and status as an autoantigen is 100% for the 48
molecules studied, whereas the negative predictive value is
73%, indicating that additional mechanisms play a role in
selection of some molecules as autoantigens. It is notewor-
thy that most of the uncleaved molecules are nucleoprotein
complexes (e.g., components of nucleosomes and small nu-
clear ribonucleoproteins); we are in the process of defining
whether these molecules undergo distinct structural modi-
fications during unique forms of apoptotic cell death. In-
deed, there are several other components of CTL granules
that might play a role in this regard.
Interestingly, the autoantigens susceptible to cleavage by
granzyme B include antigens that are targeted across the
spectrum of autoimmune rheumatic diseases. The striking
correlation of specific autoantibody response with unique
biologic phenotype (e.g., Mi-2 in dermatomyositis and to-
poisomerase I in diffuse scleroderma) raises the question of
how this disease specificity arises if a common mechanism
(CTL granule–induced death) is responsible for targeting of
this group of molecules. Although this remains unclear, the
immunizing tissue and initiating stimulus may play impor-
tant roles in focusing subsequent, self-sustaining injury.
Several of the cleaved molecules (PARP, U1-70kD, Ki-
67, SRP-72, topoisomerase I [Fig. 1 A], DNA-PKcs,
NuMA [reference 21], Mi-2, La, PMS1, PMS2, and
NOR-90 [data not shown]) are also cleaved by effector
caspases during apoptosis but at different sites in each case.
Frequently, the granzyme B and caspase-3 cleavage sites are
close to each other in the primary sequence. The striking
linkage of susceptibility to cleavage by both caspases and
granzyme B in these substrates (but at different sites) sug-
gests that the two different families of apoptotic proteases
recognize two distinct structural features of a common mo-
tif that have been targeted during independent evolution of
the apoptotic cysteine and serine protease families. The
likelihood that a functional motif has been targeted by the
apoptosis-specific proteases is further underscored by the
observation that the granzyme B cleavage sites in several
molecules (e.g., fibrillarin, PARP, and PMS1) are highly
conserved, even in drosophila and yeast. This striking con-
servation of sequence at granzyme B cleavage sites in or-
ganisms in which CTLs have not yet evolved implies that
an important, as yet undefined function is served by these
regions that is altered by proteolysis. This new, extended
family of granzyme B substrates therefore provides a pow-
erful tool with which to explore the evolution and biologi-
cal functions of the aspartic acid–specific apoptotic pro-
teases and the specific mechanisms underlying CTL
granule–induced cell death.
Granzyme B Cleavage Sites in Autoantigens Contain Amino
Acids in P2 and P3 Positions That Are Preferred by Granzyme B
but Are Not Tolerated by Group III Caspases. Using a com-
binatorial scanning tetrapeptide library, the specificity of
granzyme B and caspases has recently been determined (29,
30) and divides the caspases into three distinct groups.
Group II caspases have a DXXD specificity and act down-
stream in apoptosis as effector proteases, cleaving substrates
that have homeostatic and structural functions (34). In con-
Figure 9. Caspase-8 does not cleave endogenous autoantigens that are
granzyme B substrates. HeLa lysate (in which endogenous caspases had
been inactivated by 1 mM IAA) was incubated with 5 mM DTT in the
absence (lanes 1, 4, 7, 9, 11, and 13) or presence (lanes 2, 5, 8, 10, 12, and
14) of 50 nM caspase-8 for 1 h at 378C. In the lysates shown in lanes 3
and 6, omission of IAA permitted caspase-8 to activate endogenous effec-
tor caspases. After terminating the reactions, 75-mg amounts of sample
were electrophoresed in each gel lane. Autoantigens were detected by
blotting with monospecific patient sera. In lanes 1–6, open and solid ar-
rowheads denote the SDS-PAGE migration positions of the intact anti-
gens and the caspase-8–induced fragments, respectively. Radiolabeled
PMS1 and PMS2 (generated by in vitro transcription/translation) were
also not cleaved by purified caspase-8 (data not shown).823 Casciola-Rosen et al.
trast, the group III caspases prefer tetrapeptide substrates
with I, V, or L in P4, E, D, or Q in P3, and H, I, T, W, or
V in the P2 position (29). Whereas granzyme B has a simi-
lar specificity to the group III caspases, it has a broader sub-
strate specificity in the P3 and P2 positions. Thus, granzyme
B will robustly cleave substrates containing G or S in P3
(not tolerated by group III caspases) and prefers P, A, N,
and Q in P2 (none of which are tolerated by group III
caspases). Interestingly, 10 of 11 proven granzyme B cleav-
age sites in autoantigens contain residues that are preferred
by granzyme B but are poorly tolerated by group III
caspases (molecules contain P [7], A [2], or S [1] in the P2
position; four cleavage sites also contain G or S in P3; Table
I). Consistent with this observation is the demonstration
that none of these substrates could be cleaved by caspase-8
(Fig. 9). In contrast, procaspase-3 and -7, which are not au-
toantigens, are efficiently cleaved by both caspase-8 and
granzyme B at the same sites, generating identical frag-
ments (33). This marked skewing of granzyme B cleavage
sites in autoantigens away from P2 and P3 residues that are
preferred by both granzyme B and group III caspases
strongly suggests that unique cleavage by granzyme B plays
a role in selection of targets in this spectrum of autoim-
mune disease.
Generation of Granzyme B–specific Autoantigen Fragments Is
Favored when Caspases Are Inhibited. We have previously
demonstrated that DNA-PKcs, NuMA, and PARP are
cleaved by both caspase-3 and granzyme B and that the
most prominent fragments generated in lysates and intact
cells reflect the relative cleavage efficiencies of the two pro-
teases (21). The studies reported here extend those obser-
vations to numerous additional autoantigens (Mi-2, Ki-67,
U1-70kD, topoisomerase I, and SRP-72; Fig. 1 A and Fig.
6). Where cleavage of a substrate by granzyme B is equal to
or more efficient than that by caspase-3, granzyme B–spe-
cific fragments are generated in the LAK/K562 system
(e.g., DNA-PKcs, Mi-2, and topoisomerase I; Table II). In
contrast, where cleavage by granzyme B is less efficient
than cleavage by caspases (e.g., PARP, U1-70kD, SRP-72,
and topoisomerase I [72- and 74-kD fragments]), effective
generation of the granzyme B–specific fragments is only
seen in intact cells when caspase activity is inhibited. This
observation focuses attention on defining potential im-
munizing microenvironments and proimmune insults in
which such circumstances may arise in vivo. Relevant pos-
sibilities include conditions where viral or endogenous
caspase inhibitors are expressed (35–40), as well as in long-
lived cells or tumor cells that express low levels of specific
effector caspases (41, 42).
CTL Granule–induced Death and Autoimmunity. Hu-
man systemic autoimmune diseases represent a highly com-
plex disease spectrum, with numerous variables affecting
individual susceptibility, initiation, and tissue targets. By
demonstrating that the autoantigens targeted across the
spectrum of these diseases are unified by their susceptibility
to efficient cleavage by granzyme B, with the generation of
unique fragments not produced during any other form of
cell death, these studies focus attention on the role of the
CTL granule pathway in initiation of autoimmunity.
Where substrates are cleaved by both caspases and gran-
zyme B, effective generation of unique granzyme B frag-
ments is dependent upon relative inhibition of the caspases
(Fig. 6; reference 21). We therefore propose that during
proimmune (43) intracellular infections occurring in a mi-
croenvironment in which caspase activity is under relative
inhibition, production of unique granzyme B fragments is
favored. In susceptible individuals in whom clearance of
apoptotic material might be impaired (44, 45), suprathresh-
old amounts of these fragments accumulate and are effec-
tively captured and presented by dendritic cells (46–49).
The resulting immune response is directed against products
of CTL granule–induced death, generating an autoamplify-
ing injury characteristic of these self-sustaining diseases.
The recent observation of tumor-specific CTLs in parane-
oplastic cerebellar degeneration suggests that such a mecha-
nism may be more broadly applicable to other autoimmune
syndromes (50).
We thank Dr. Allan Gelber (Johns Hopkins University) for assistance with statistical analysis and Amy Cox
and Steven Morris for excellent technical help.
These studies were supported by National Institutes of Health grants AR44684 (to L. Casciola-Rosen),
DE12354 (to A. Rosen), and 5T32-AI07247 (to D. Ulanet and W.B. Wong), the SLE Foundation, the
Scleroderma Research Foundation, and the Schauman Lupus Research Fund. A. Rosen is a Pew Scholar in
the Biomedical Sciences and is supported by a Burroughs Wellcome Fund Translational Research award. F.
Andrade is supported by a Fulbright/Consejo Nacional de Ciencia y Tecnologia, Mexico scholarship.
Address correspondence to Antony Rosen, Johns Hopkins University School of Medicine, 720 Rutland
Ave., Ross 1059, Baltimore, MD 21205. Phone: 410-955-0139; Fax: 410-955-0964; E-mail:
arosen@jhmi.edu
Submitted: 21 May 1999 Revised: 19 July 1999 Accepted: 20 July 1999824 Susceptibility to Granzyme B Cleavage Predicts Autoantigen Status
References
1. Hardin, J.A., D.R. Rahn, C. Shen, M.R. Lerner, S.L.
Wolin, M.D. Rosa, and J.A. Steitz. 1982. Antibodies from
patients with connective tissue diseases bind specific subsets
of cellular RNA–protein particles. J. Clin. Invest. 70:141–147.
2. Tan, E.M. 1989. Antinuclear antibodies: diagnostic markers
for autoimmune diseases and probes for cell biology. Adv.
Immunol. 44:93–151.
3. Casciola-Rosen, L.A., G. Anhalt, and A. Rosen. 1994. Au-
toantigens targeted in systemic lupus erythematosus are clus-
tered in two populations of surface structures on apoptotic
keratinocytes. J. Exp. Med. 179:1317–1330.
4. Mamula, M.J. 1993. The inability to process a self-peptide al-
lows autoreactive T cells to escape tolerance. J. Exp. Med.
177:567–571.
5. Sercarz, E.E., P.V. Lehmann, A. Ametani, G. Benichou, A.
Miller, and K. Moudgil. 1993. Dominance and crypticity of
T cell antigenic determinants. Annu. Rev. Immunol. 11:729–766.
6. Casciola-Rosen, L.A., D.K. Miller, G.J. Anhalt, and A.
Rosen. 1994. Specific cleavage of the 70-kDa protein com-
ponent of the U1 small nuclear ribonucleoprotein is a charac-
teristic biochemical feature of apoptotic cell death. J. Biol.
Chem. 269:30757–30760.
7. Casciola-Rosen, L.A., G.J. Anhalt, and A. Rosen. 1995.
DNA-dependent protein kinase is one of a subset of autoan-
tigens specifically cleaved early during apoptosis. J. Exp. Med.
182:1625–1634.
8. Greidinger, E.L., D.K. Miller, T.-T. Yamin, L. Casciola-
Rosen, and A. Rosen. 1996. Sequential activation of three
distinct ICE-like activities in Fas-ligated Jurkat cells. FEBS
Lett. 390:299–303.
9. Casiano, C.A., S.J. Martin, D.R. Green, and E.M. Tan.
1996. Selective cleavage of nuclear autoantigens during
CD95 (Fas/APO-1)-mediated T cell apoptosis. J. Exp. Med.
184:765–770.
10. Utz, P.J., M. Hottelet, T.M. Le, S.J. Kim, M.E. Geiger, W.J.
van Venrooij, and P. Anderson. 1998. The 72-kDa compo-
nent of signal recognition particle is cleaved during apoptosis.
J. Biol. Chem. 273:35362–35370.
11. Cryns, V., and J. Yuan. 1998. Proteases to die for. Genes
Dev. 12:1551–1570.
12. Izquierdo, M., A. Grandien, L.M. Criado, S. Robles, E. Le-
onardo, J.P. Albar, G.G. de Buitrago, and A.C. Martinez.
1999. Blocked negative selection of developing T cells in
mice expressing the baculovirus p35 caspase inhibitor.
EMBO (Eur. Mol. Biol. Organ.) J. 18:156–166.
13. Rosen, A., and L. Casciola-Rosen. 1999. Autoantigens as
substrates for apoptotic proteases: implications for the patho-
genesis of systemic autoimmune disease. Cell Death Differ.
6:6–12.
14. Shi, L., C.-M. Kam, J.C. Powers, R. Aebersold, and A.H.
Greenberg. 1992. Purification of three cytotoxic lymphocyte
granule serine proteases that induce apoptosis through dis-
tinct substrate and target cell interactions. J. Exp. Med. 176:
1521–1529.
15. Heusel, J.W., R.L. Wesselschmidt, S. Shresta, J.H. Russell,
and T.J. Ley. 1994. Cytotoxic lymphocytes require granzyme
B for the rapid induction of DNA fragmentation and apopto-
sis in allogeneic target cells. Cell. 76:977–987.
16. Shresta, S., D.M. MacIvor, J.W. Heusel, J.H. Russell, and
T.J. Ley. 1995. Natural killer and lymphokine-activated
killer cells require granzyme B for the rapid induction of ap-
optosis in susceptible target cells. Proc. Natl. Acad. Sci. USA.
92:5679–5683.
17. Henkart, P.A. 1994. Lymphocyte-mediated cytotoxicity: two
pathways and multiple effector molecules. Immunity. 1:343–346.
18. Shresta, S., C.T. Pham, D.A. Thomas, T.A. Graubert, and
T.J. Ley. 1998. How do cytotoxic lymphocytes kill their tar-
gets? Curr. Opin. Immunol. 10:581–587.
19. Sarin, A., M.S. Williams, M.A. Alexander-Miller, J.A. Ber-
zofsky, C.M. Zacharchuk, and P.A. Henkart. 1997. Target
cell lysis by CTL granule exocytosis is independent of ICE/
Ced-3 family proteases. Immunity. 6:209–215.
20. MacDonald, G., L. Shi, C. Vande Velde, J. Lieberman, and
A.H. Greenberg. 1999. Mitochondria-dependent and -inde-
pendent regulation of granzyme B–induced apoptosis. J. Exp.
Med. 189:131–144.
21. Andrade, F., S. Roy, D.W. Nicholson, N.A. Thornberry, A.
Rosen, and L. Casciola-Rosen. 1998. Granzyme B directly
and efficiently cleaves several downstream substrates: implica-
tions for CTL-induced apoptosis. Immunity. 8:451–460.
22. Casciola-Rosen, L., A. Pluta, P. Plotz, K. Nagaraju, A. Cox,
S. Morris, and A. Rosen. 1998. hPMS1 is a novel, frequently
targeted myositis autoantigen which is cleaved by granzyme
B but not by caspases during apoptosis. Arthritis Rheum. 41:
S127. (Abstr.)
23. Casciola-Rosen, L.A., D.W. Nicholson, T. Chong, K.R.
Rowan, N.A. Thornberry, D.K. Miller, and A. Rosen. 1996.
Apopain/CPP32 cleaves proteins that are essential for cellular
repair: a fundamental principle of apoptotic death. J. Exp.
Med. 183:1957–1964.
24. Utz, P.J., and P. Anderson. 1998. Posttranslational protein
modifications, apoptosis, and the bypass of tolerance to au-
toantigens. Arthritis Rheum. 41:1152–1160.
25. Darmon, A.J., D.W. Nicholson, and R.C. Bleackley. 1995.
Activation of the apoptotic protease CPP32 by cytotoxic
T-cell-derived granzyme B. Nature. 377:446–448.
26. Chinnaiyan, A.M., W.L. Hanna, K. Orth, H.J. Duan, G.G.
Poirier, C.J. Froelich, and V.M. Dixit. 1996. Cytotoxic
T-cell-derived granzyme B activates the apoptotic protease
ICE-LAP3. Curr. Biol. 6:897–899.
27. Quan, L.T., M. Tewari, K. O’Rourke, V. Dixit, S.J. Snipas,
G.G. Poirier, C. Ray, D.J. Pickup, and G.S. Salveson. 1996.
Proteolytic activation of the cell death protease Yama/
CPP32 by granzyme B. Proc. Natl. Acad. Sci. USA. 93:1972–
1976.
28. Martin, S.J., G.P. Amarente-Mendes, L.F. Shi, T.H.
Chuang, C.A. Casiano, G.A. O’Brien, P. Fitzgerald, E.M.
Tan, G.M. Bokoch, A.H. Greenberg, et al. 1996. The cyto-
toxic cell protease granzyme B initiates apoptosis in a cell-
free system by proteolytic processing and activation of the
ICE/CED-3 family protease, CPP32, via a novel two-step
mechanism. EMBO (Eur. Mol. Biol. Organ.) J. 15:2407–2416.
29. Thornberry, N.A., T.A. Ranon, E.P. Pieterson, D.M.
Rasper, T. Timkey, M. Garcia-Calvo, V.M. Houtzager, P.A.
Nordstrom, S. Roy, J.P. Vaillancourt, et al. 1997. A combi-
natorial approach defines specificities of members of the
caspase family and granzyme B. Functional relationships es-
tablished for key mediators of apoptosis. J. Biol. Chem. 272:
17907–17911.
30. Harris, J.L., E.P. Peterson, D. Hudig, N.A. Thornberry, and
C.S. Craik. 1998. Definition and redesign of the extended
substrate specificity of granzyme B. J. Biol. Chem. 273:
27364–27373.
31. Froelich, C.J., W.L. Hanna, G.G. Poirier, P.J. Duriez, D.825 Casciola-Rosen et al.
D’Amours, G.S. Salvesen, E.S. Alnemri, W.C. Earnshaw,
and G.M. Shah. 1996. Granzyme B perforin-mediated apop-
tosis of jurkat cells results in cleavage of poly(ADP-ribose)
polymerase to the 89-kDa apoptotic fragment and less abun-
dant 64-kDa fragment. Biochem. Biophys. Res. Commun. 227:
658–665.
32. Nagata, S. 1997. Apoptosis by death factor. Cell. 88:355–365.
33. Salvesen, G.S., and V.M. Dixit. 1997. Caspases: intracellular
signaling by proteolysis. Cell. 91:443–446.
34. Nicholson, D.W., and N.A. Thornberry. 1997. Caspases:
killer proteases. TIBS (Trends Biochem. Sci.). 22:299–306.
35. Beidler, D.R., M. Tewari, P.D. Friesen, G. Poirier, and
V.M. Dixit. 1995. The baculovirus p35 protein inhibits Fas-
and tumor necrosis factor-induced apoptosis. J. Biol. Chem.
270:16526–16528.
36. Bump, N.J., M. Hackett, M. Hugunin, S. Seshagiri, K.
Brady, P. Chen, C. Ferenz, S. Franklin, T. Ghayur, P. Li, et
al. 1995. Inhibition of ICE family proteases by baculovirus
antiapoptotic protein p35. Science. 269:1885–1888.
37. Deveraux, Q.L., N. Roy, H.R. Stennicke, T. Van Arsdale,
Q. Zhou, S.M. Srinivasula, E.S. Alnemri, G.S. Salvesen, and
J.C. Reed. 1998. IAPs block apoptotic events induced by
caspase-8 and cytochrome c by direct inhibition of distinct
caspases. EMBO (Eur. Mol. Biol. Organ.) J. 17:2215–2223.
38. Srinivasula, S.M., M. Ahmad, S. Ottilie, F. Bullrich, S.
Banks, Y. Wang, T. Fernandes-Alnemri, C.M. Croce, G.
Litwack, K.J. Tomaselli, et al. 1997. FLAME-1, a novel
FADD-like anti-apoptotic molecule that regulates Fas/
TNFR1-induced apoptosis. J. Biol. Chem. 272:18542–18545.
39. Irmler, M., M. Thome, M. Hahne, P. Schneider, B. Hof-
mann, V. Steiner, J.L. Bodmer, M. Schröter, K. Burns, C.
Mattmann, et al. 1997. Inhibition of death receptor signals by
cellular FLIP. Nature. 388:190–195.
40. Thome, M., P. Schneider, K. Hofmann, H. Fickenscher, E.
Meinl, F. Neipel, C. Mattmann, K. Burns, J.L. Bodmer,
M. Schröter, et al. 1997. Viral FLICE-inhibitory proteins
(FLIPs) prevent apoptosis induced by death receptors. Nature.
386:517–521.
41. Krajewska, M., H.G. Wang, S. Krajewski, J.M. Zapata, A.
Shabaik, R. Gascoyne, and J.C. Reed. 1997. Immunohis-
tochemical analysis of in vivo patterns of expression of
CPP32 (caspase-3), a cell death protease. Cancer Res. 57:
1605–1613.
42. Krajewski, S., R.D. Gascoyne, J.M. Zapata, M. Krajewska, S.
Kitada, M. Chhanabhai, D. Horsman, K. Berean, L.D. Piro,
I. Fugier-Vivier, et al. 1997. Immunolocalization of the
ICE/Ced-3-family protease, CPP32 (caspase-3), in non-
Hodgkin’s lymphomas, chronic lymphocytic leukemias, and
reactive lymph nodes. Blood. 89:3817–3825.
43. Matzinger, P. 1994. Tolerance, danger, and the extended
family.  Annu. Rev. Immunol. 12:991–1045.
44. Herrmann, M., R.E. Voll, O.M. Zoller, M. Hagenhofer,
B.B. Ponner, and J.R. Kalden. 1998. Impaired phagocytosis
of apoptotic cell material by monocyte-derived macrophages
from patients with systemic lupus erythematosus. Arthritis
Rheum. 41:1241–1250.
45. Botto, M., C. Dell’Agnola, A.E. Bygrave, E.M. Thompson,
H.T. Cook, F. Petry, M. Loos, P.P. Pandolfi, and M.J.
Walport. 1998. Homozygous C1q deficiency causes glomer-
ulonephritis associated with multiple apoptotic bodies. Nat.
Genet. 19:56–59.
46. Albert, M.L., S.F.A. Pearce, L.M. Francisco, B. Sauter, P.
Roy, R.L. Silverstein, and N. Bhardwaj. 1998. Immature
dendritic cells phagocytose apoptotic cells via avb5 and
CD36 and cross-present antigens to cytotoxic T lympho-
cytes.  J. Exp. Med. 188:1359–1368.
47. Albert, M.L., B. Sauter, and N. Bhardwaj. 1998. Dendritic
cells acquire antigen from apoptotic cells and induce class I
restricted CTLs. Nature. 392:86–89.
48. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M.
Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, et al.
1998. Efficient presentation of phagocytosed cellular frag-
ments on the major histocompatibility complex class II prod-
ucts of dendritic cells. J. Exp. Med. 11:2163–2173.
49. Rovere, P., C. Vallinoto, A. Bondaza, M.C. Crosti, M.
Rescigno, P. Ricciardi-Castagnoli, C. Rugarli, and A.A.
Manfredi. 1998. Bystander apoptosis triggers dendritic cell
maturation and antigen-presenting function. J. Immunol. 161:
4467–4471.
50. Albert, M.L., J.C. Darnell, A. Bender, L.M. Francisco, N.
Bhardwaj, and R.B. Darnell. 1998. Tumor-specific killer
cells in paraneoplastic cerebellar degeneration. Nat. Med. 11:
1321–1324.